Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Altanserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.88 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.73 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.73 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.73 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.73 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.73 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.88 |
| ▸ | HPGD | P15428 | 3/20 | 0.88 |
| ▸ | HTR2C | P28335 | 3/20 | 0.88 |
| ▸ | TSHR | P16473 | 2/20 | 0.88 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.88 |
| ▸ | HTR1A | P08908 | 2/20 | 0.88 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.88 |
| ▸ | DRD2 | P14416 | 2/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Altanserin SCHEMBL124036 | 1.00 | HTR2A (0.88) | HTR2ACYP2D6CYP3A4HPGDHTR2C | |
| Altanserin SCHEMBL404849 | 0.94 | HTR2A (1.00) | HTR2ACYP2D6CYP3A4HPGDHTR2C | |
| Altanserin SCHEMBL12629110 | 0.94 | HTR2A (1.00) | HTR2ACYP2D6CYP3A4HPGDHTR2C | |
| Altanserin SCHEMBL30136524 | 0.94 | HTR2A (1.00) | HTR2ACYP2D6CYP3A4HPGDHTR2C | |
| Altanserin SCHEMBL30136526 | 0.94 | HTR2A (1.00) | HTR2ACYP2D6CYP3A4HPGDHTR2C | |
| Altanserin SCHEMBL15662949 | 0.93 | HTR2A (1.00) | HTR2ACYP2D6CYP3A4HPGDHTR2C | |
| Ketanserin SCHEMBL4142325 | 0.91 | CYP2D6 (1.00) | HTR2ACYP2D6CYP3A4HPGDHTR2C | |
| Ketanserin SCHEMBL362930 | 0.91 | CYP2D6 (1.00) | HTR2ACYP2D6CYP3A4HPGDHTR2C | |
| Ketanserin SCHEMBL29772991 | 0.91 | CYP2D6 (1.00) | HTR2ACYP2D6CYP3A4HPGDHTR2C | |
| Ketanserin SCHEMBL1651721 | 0.90 | CYP2D6 (1.00) | HTR2ACYP2D6CYP3A4HPGDHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20090220429-A1 | METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | METIS CURA EHF (IS) | 2009-09-03 | — | — | US | claimed |
| EP-1861003-A1 | A METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | Mentis Cura ehf. (IS) | 2007-12-05 | — | — | EP | claimed |
| WO-2006094797-A1 | A METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | MENTIS CURA EHF. (IS) | 2006-09-14 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | TRIS PHARMA INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12514818-B2 | Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system | TRIS PHARMA, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-6323236-B2 | PSYCHOLOGICAL DISORDERS | UNIVERSITY OF CINCINNATI | 2001-11-27 | — | — | US | disclosed |
| US-20010023254-A1 | Psychological disorders | CINCINNATI, UNIVERSITY OF | 2001-09-20 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | SI, FABP2, FABP6 | HTR2A 691/4885ADRA2B 962/4885ADRA2C 1030/4885 |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | SI, GRPR, FABP2 | HTR2A 220/4885ADRA2B 148/4885ADRA2C 454/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | HTR2A 848/4885ADRA2B 1165/4885ADRA2C 902/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | HTR2A 857/4885ADRA2B 1110/4885ADRA2C 2885/4885 |
| US-20010023254-A1 | Psychological disorders | DRD2, DRD3, DRD1 | HTR2A 17/4885ADRA2B 222/4885ADRA2C 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.